Clinical Roundup Durvalumab + enfortumab improves survival in patients with MIBC, VOLGA phase III trial finds November 13, 2026Vol.52 No.42
Clinical Roundup Piktor regimen yields 33% confirmed ORR in advanced endometrial cancer, phase II study finds November 13, 2026Vol.52 No.42
Clinical Roundup Roginolisib regimens revert immune suppression in immunotherapy-resistant NSCLC, phase I/II study finds November 13, 2026Vol.52 No.42
Clinical Roundup Pasritamig-based immunotherapy regimen shows 73% PSA response rate in advanced prostate cancer in phase I study November 13, 2026Vol.52 No.42
Clinical Roundup Two “forever chemicals” are associated with higher risk of aggressive breast cancer, NIH analysis finds November 13, 2026Vol.52 No.42
Clinical Roundup Pitt-led study finds that most people have genetic variants that affect how they processes medications November 13, 2026Vol.52 No.42
Clinical Roundup Broad genomic testing linked to longer survival in advanced NSCLC, Emory-led study finds November 13, 2026Vol.52 No.42
Clinical Roundup Tarlatamab + durvalumab extends survival for patients with aggressive small cell lung cancer, phase III trial finds November 06, 2026Vol.52 No.41
Clinical Roundup Median OS not reached in metastatic prostate cancer treated with investigational SV-102, phase I study finds November 06, 2026Vol.52 No.41
Clinical Roundup CRC incidence rates are rising among all age groups, SEER data analysis finds November 06, 2026Vol.52 No.41